FIELD: medicine.
SUBSTANCE: patient is administered with five separate doses of VEGF antagonist at intervals of 6 weeks for the treatment of diabetic macular edema. VEGF antagonist is then additionally administered once every 8 weeks or once every 12 weeks. VEGF antagonist contains sequences SEQ ID NO:1 and SEQ ID NO:2.
EFFECT: group of inventions provides for an effective method for the treatment of diabetic macular edema and the use of less frequent administration of doses of a drug than it is provided in treatment schemes approved nowadays.
48 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING ANTIBODIES TO IL6R FOR TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF THEIR USE | 2016 |
|
RU2747193C2 |
| COMBINATION PREPARATIONS WITH CYTOKINE ANTAGONIST AND CORTICOSTEROID | 2010 |
|
RU2526161C2 |
| COMBINATION DRUG CONTAINING CORTICOSTEROID AND EXOSOMES | 2010 |
|
RU2557897C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED | 2016 |
|
RU2712623C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
